Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

181. Oral versus intravenous fluoropyrimidines for colorectal cancer. (PubMed)

Oral versus intravenous fluoropyrimidines for colorectal cancer. Patients prefer oral to intravenous (IV) palliative chemotherapy, provided that oral therapy is not less effective. We compared the efficacy and safety of oral and IV fluoropyrimidines for treatment of colorectal cancer (CRC).To compare the effects of oral and IV fluoropyrimidine chemotherapy in patients treated with curative or palliative intent for CRC.We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2016

2017 Cochrane

182. Aspirin Prevention of Colorectal Cancer: Focus on NF-κB Signalling and the Nucleolus (PubMed)

Aspirin Prevention of Colorectal Cancer: Focus on NF-κB Signalling and the Nucleolus Overwhelming evidence indicates that aspirin and related non-steroidal anti-inflammatory drugs (NSAIDs) have anti-tumour activity and the potential to prevent cancer, particularly colorectal cancer. However, the mechanisms underlying this effect remain hypothetical. Dysregulation of the nuclear factor-kappaB (NF-κB) transcription factor is a common event in many cancer types which contributes to tumour (...) initiation and progression by driving expression of pro-proliferative/anti-apoptotic genes. In this review, we will focus on the current knowledge regarding NSAID effects on the NF-κB signalling pathway in pre-cancerous and cancerous lesions, and the evidence that these effects contribute to the anti-tumour activity of the agents. The nuclear organelle, the nucleolus, is emerging as a central regulator of transcription factor activity and cell growth and death. Nucleolar function is dysregulated

Full Text available with Trip Pro

2017 Biomedicines

183. Protracted Inhibition of Vascular Endothelial Growth Factor Signaling Improves Survival in Metastatic Colorectal Cancer: A Systematic Review. (PubMed)

Protracted Inhibition of Vascular Endothelial Growth Factor Signaling Improves Survival in Metastatic Colorectal Cancer: A Systematic Review. Clinical data suggest that beyond-progression, the blockade of angiogenesis is associated with improved survivals in colorectal cancer. We conducted a systematic review to investigate the therapeutic effects of antiangiogenic drugs administered as later lines of treatment in patients already progressed to a previous anti-VEGF based treatment. An extensive

Full Text available with Trip Pro

2017 Journal of translational internal medicine

184. Efficacy of Blended Cognitive Behavior Therapy for High Fear of Recurrence in Breast, Prostate, and Colorectal Cancer Survivors: The SWORD Study, a Randomized Controlled Trial

Efficacy of Blended Cognitive Behavior Therapy for High Fear of Recurrence in Breast, Prostate, and Colorectal Cancer Survivors: The SWORD Study, a Randomized Controlled Trial Purpose Fear of cancer recurrence (FCR) is a common problem experienced by cancer survivors. Approximately one third of survivors report high FCR. This study aimed to evaluate whether blended cognitive behavior therapy (bCBT) can reduce the severity of FCR in cancer survivors curatively treated for breast, prostate (...) , or colorectal cancer. Patients and Methods This randomized controlled trial included 88 cancer survivors with high FCR (Cancer Worry Scale score ≥ 14) from 6 months to 5 years after cancer treatment. Participants were randomly allocated (ratio 1:1, stratified by cancer type) to receive bCBT, including five face-to face and three online sessions (n = 45) or care as usual (CAU; n = 43). Participants completed questionnaires at baseline (T0) and 3 months later (T1). The intervention group completed bCBT

2017 EvidenceUpdates

185. Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancerologie Digestive Database

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancerologie Digestive Database Purpose Factors contributing to early mortality after initiation of treatment of metastatic colorectal cancer are poorly understood. Materials and Methods Data from 22,654 patients enrolled in 28 randomized phase III trials contained in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were pooled (...) in the external validation set, both overall and within patient subgroups. Conclusion A validated clinical nomogram has been developed to quantify the risk of early death for individual patients during initial treatment of metastatic colorectal cancer. This tool may be used for patient eligibility assessment or risk stratification in future clinical trials and to identify patients requiring more or less aggressive therapy and additional supportive measures during and after treatment.

Full Text available with Trip Pro

2017 EvidenceUpdates

186. The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations

The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations The clinical effectiveness of different (...) surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations Atkin W, Brenner A, Martin J, Wooldrage K, Shah U, Lucas F, Greliak P, Pack K, Kralj-Hans I, Thomson A, Perera S, Wood J, Miles A, Wardle J, Kearns B, Tappenden P, Myles J, Veitch A & Duffy S W Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation

2017 Health Technology Assessment (HTA) Database.

187. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economi

The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economi The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review (...) and economic evaluation Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} In previously untreated RAS WT metastatic colorectal cancer, adding either cetuximab or panitumumab

2017 NIHR HTA programme

188. Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis

Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (...) (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Faecal immunochemical testing is likely to be clinically and cost- effective in primary care for triaging people presenting with lower abdominal symptoms, but who are at low risk for colorectal cancer. {{author}} {{($index

2017 NIHR HTA programme

189. A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent

A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page (...) not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} For people after resection for colorectal cancer with curative intent, intensive compared with no scheduled follow-up identified more treatable recurrences, but there was no reduction in mortality. {{author}} {{($index

2017 NIHR HTA programme

190. Another brick in the large wall against colorectal cancer: a commentary on effectiveness of screening colonoscopy (PubMed)

Another brick in the large wall against colorectal cancer: a commentary on effectiveness of screening colonoscopy 28713863 2018 11 13 2415-1289 2 2017 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Another brick in the large wall against colorectal cancer: a commentary on effectiveness of screening colonoscopy. 59 10.21037/tgh.2017.06.02 Glazer Yair Y Department of Surgery A, Soroka University Medical Center, Beer Sheva, Israel. Perry Zvi H ZH Department of Surgery (...) A, Soroka University Medical Center, Beer Sheva, Israel. Department of Epidemiology, Ben-Gurion University of the Negev, Beer-Sheva, Israel. Avital Itzhak I Department of Surgery A, Soroka University Medical Center, Beer Sheva, Israel. Soroka University Comprehensive Cancer Center, Beer-Sheva, Israel. Department of Healthcare Sciences, Ben-Gurion University, Beer-Sheva, Israel. eng Editorial Comment 2017 06 30 China Transl Gastroenterol Hepatol 101683450 2415-1289 Gut. 2016 Oct 12;: 27733426 Conflicts

Full Text available with Trip Pro

2017 Translational gastroenterology and hepatology

191. Mortality and Survival after Surgical Treatment of Colorectal Cancer in Patients Aged over 80 Years (PubMed)

Mortality and Survival after Surgical Treatment of Colorectal Cancer in Patients Aged over 80 Years The purpose of this study was to identify the clinical factors and tumor characteristics that predict the outcome of colorectal cancer patients aged >80 years.The data of 186 patients aged >80 years with colorectal cancer were collected from a computer database, and the variables were analyzed by both uni- and multivariate analyses.The 30-day mortality was 4% and the 90-day mortality 10%. The 1 (...) were significant predictors of survival, but in the Cox regression model, only radical operation and venous invasion were independent prognostic factors for survival.After good surgical selection, low early mortality and acceptable long-term survival can be achieved even in the oldest old patients with colorectal cancer. However, low early mortality seems to underestimate the effects of surgery during the first postoperative year.

Full Text available with Trip Pro

2017 Gastrointestinal tumors

192. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. (PubMed)

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. Epidermal growth factor receptor (EGFR) inhibitors prevent cell growth and have shown benefit in the treatment of metastatic colorectal cancer, whether used as single agents or in combination with chemotherapy. Clear benefit has been shown in trials of EGFR monoclonal antibodies (EGFR MAb) but not EGFR tyrosine kinase inhibitors (EGFR TKI). However, there is ongoing debate as to which patient populations gain (...) maximum benefit from EGFR inhibition and where they should be used in the metastatic colorectal cancer treatment paradigm to maximise efficacy and minimise toxicity.To determine the efficacy, safety profile, and potential harms of EGFR inhibitors in the treatment of people with metastatic colorectal cancer when given alone, in combination with chemotherapy, or with other biological agents.The primary outcome of interest was progression-free survival; secondary outcomes included overall survival

2017 Cochrane

193. Atezolizumab (Tecentriq) and Cobimetinib (Cotellic) for advanced/metastatic colorectal cancer - third line

Atezolizumab (Tecentriq) and Cobimetinib (Cotellic) for advanced/metastatic colorectal cancer - third line Atezolizumab (Tecentriq) and Cobimetinib (Cotellic) for advanced/metastatic colorectal cancer – third line | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search (...) will not return all technologies currently in development as these outputs are produced as required for our stakeholders. > > > Atezolizumab (Tecentriq) and Cobimetinib (Cotellic) for advanced/metastatic colorectal cancer – third line Atezolizumab (Tecentriq) and Cobimetinib (Cotellic) for advanced/metastatic colorectal cancer – third line June 2017 The combination of atezolizumab (Tecentriq), given by injection, and cobimetinib (Cotellic), given orally, is being developed to increase the options available

2017 NIHR Innovation Observatory

194. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. (PubMed)

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic colorectal cancer, but the optimal choice of the initial biologic therapy in previously untreated patients is unknown.To determine if the addition (...) colorectal cancer whose tumors were KRAS wt chose to take either the mFOLFOX6 regimen or the FOLFIRI regimen as chemotherapy and were randomized to receive either cetuximab (n = 578) or bevacizumab (n = 559). The last date of follow-up was December 15, 2015.Cetuximab vs bevacizumab combined with either mFOLFOX6 or FOLFIRI chemotherapy regimen chosen by the treating physician and patient.The primary end point was overall survival. Secondary objectives included progression-free survival and overall

Full Text available with Trip Pro

2017 JAMA

195. Effectiveness of self-administered decision aids for people invited to participate in colorectal cancer screening: a systematic review protocol. (PubMed)

Effectiveness of self-administered decision aids for people invited to participate in colorectal cancer screening: a systematic review protocol. The objective is to assess the effectiveness of self-administered decision aids for people invited to participate in colorectal cancer screening. We will evaluate effects on informed choice, decisional conflict, knowledge, and participation in colorectal cancer screening.

2017 JBI database of systematic reviews and implementation reports

196. Development and validation of risk prediction equations to estimate survival in patients with colorectal cancer: cohort study. (PubMed)

Development and validation of risk prediction equations to estimate survival in patients with colorectal cancer: cohort study. Objective To develop and externally validate risk prediction equations to estimate absolute and conditional survival in patients with colorectal cancer. Design Cohort study.Setting General practices in England providing data for the QResearch database linked to the national cancer registry.Participants 44 145 patients aged 15-99 with colorectal cancer from 947 practices (...) to derive the equations. The equations were validated in 15 214 patients with colorectal cancer from 305 different QResearch practices and 437 821 patients with colorectal cancer from the national cancer registry.Main outcome measures The primary outcome was all cause mortality and secondary outcome was colorectal cancer mortality.Methods Cause specific hazards models were used to predict risks of colorectal cancer mortality and other cause mortality accounting for competing risks, and these risk

Full Text available with Trip Pro

2017 BMJ

197. Intraoperative Ultrasound as a Screening Modality for the Detection of Liver Metastases during Resection of Primary Colorectal Cancer - A Systematic Review. (PubMed)

Intraoperative Ultrasound as a Screening Modality for the Detection of Liver Metastases during Resection of Primary Colorectal Cancer - A Systematic Review. Colorectal cancer (CRC) is one of the most common cancer diseases worldwide. One in 4 patients with CRC will have a disseminated disease at the time of diagnosis and often in the form of synchronous liver metastases. Studies suggest that up to 30% of patients have non-recognized hepatic metastases during primary surgery for CRC (...) the search engines: PubMed, Cochrane, Embase and Google. 21 studies were included in the review and the key words: intraoperative ultrasound, laparoscopic ultrasound, staging colon and rectum cancer. Results Intraoperative ultrasound showed a higher sensitivity, specificity, positive predictive value and overall accuracy for the detection liver metastases during surgery for primary CRC, compared to preoperative imaging modalities (ultrasound, computed tomography (CT) and contrast-enhanced computed

Full Text available with Trip Pro

2017 Ultrasound international open

198. Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports (PubMed)

Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports 29114600 2018 11 13 2452-1094 2 3 2017 Jul-Sep Advances in radiation oncology Adv Radiat Oncol Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports. 333-338 10.1016/j.adro.2017.06.001 Ebner Daniel K DK Hospital of the National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Sciences and Technology, Chiba (...) 05 31 2017 06 01 2017 11 9 6 0 2017 11 9 6 0 2017 11 9 6 1 epublish 29114600 10.1016/j.adro.2017.06.001 S2452-1094(17)30101-X PMC5605310 J Immunother Cancer. 2016 Sep 20;4:51 27660705 Anticancer Res. 2007 Jan-Feb;27(1B):499-503 17348433 Nat Rev Clin Oncol. 2016 Aug;13(8):516-24 26951040 Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):293-5 22560555 Oncoimmunology. 2014 May 14;3:e28780 25083318 Cancer Lett. 2015 Jan 1;356(1):82-90 24125863 Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862-70

Full Text available with Trip Pro

2017 Advances in radiation oncology

199. Indocyanine green fluorescence-guided surgery after IV injection in metastatic colorectal cancer: A systematic review. (PubMed)

Indocyanine green fluorescence-guided surgery after IV injection in metastatic colorectal cancer: A systematic review. Indocyanine green fluorescence-guided surgery (ICG-FGS) has emerged as a potential new imaging modality for improving the detection of hepatic, lymph node (LN), and peritoneal metastases in colorectal cancer (CRC) patients. The aim of this paper is to review the available literature in the clinical setting of ICG-FGS for tumoral detection in various fields of metastatic (...) colorectal disease.PubMed and Medline literature databases were searched for original articles on the use of ICG in the setting of clinical studies on colorectal cancer. The search terms used were "near-infrared fluorescence", "intraoperative imaging", "indocyanine green", "human" and "colorectal cancer".ICG fluorescence imaging (ICG-FI) is clearly supported as an intraoperative technique that allows the detection of additional superficial hepatic metastases of CRC. Data on the role of ICG-FI

2017 European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

200. Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model (PubMed)

Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model Approximately 10% of colorectal cancers harbor BRAFV600E mutations, which constitutively activate the MAPK signaling pathway. We sought to determine whether ERK inhibitor (GDC-0994)-containing regimens may be of clinical benefit to these patients based on data from in vitro (cell line) and in vivo (cell- and patient-derived xenograft) studies of cetuximab (EGFR), vemurafenib (BRAF

Full Text available with Trip Pro

2017 NPJ systems biology and applications